Billionaire Profile
George Yancopoulos
Global Rank
#2422

Image: AbhiramJuvvadi | CC BY-SA 4.0 | via Wikimedia Commons

George Yancopoulos

CEO, Pharmaceuticals
UNITED STATES
Real-Time Net Worth
$1.706B
Estimated based on Pharmaceuticals stock value as of April 20, 2026
-0.09% (24h)
Age
66
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
UNITED STATES

Biography

George Yancopoulos, born in 1959, is a prominent figure in the biopharmaceutical industry as the co-founder, President, and Chief Scientific Officer of Regeneron Pharmaceuticals. With a current estimated net worth of $1.8 billion, Yancopoulos's wealth stems primarily from his ownership stake in Regeneron, a company he helped build from the ground up. His career is marked by significant achievements in scientific research and drug development. Yancopoulos has been instrumental in the invention of numerous FDA-approved drugs and is a principal inventor of Regeneron's foundational technologies for target and drug discovery. He holds over 100 patents and has authored over 350 scientific papers. Yancopoulos is recognized as one of the most successful scientists and drug discoverers in biotech history.

Fact Checked
Verified by Editorial Team
Live Data
Updated 4/20/2026

Wealth Over Time

In-Depth Profile

Early Life and Education

George D. Yancopoulos, the son of Greek immigrants, was born in 1959. Growing up in Woodside, New York, he attended New York City public schools and showed exceptional academic abilities early on. He graduated as valedictorian of both the Bronx High School of Science, where he was also a top winner in the Westinghouse Science Talent Search in 1976, and Columbia College. Yancopoulos furthered his education at Columbia University's College of Physicians & Surgeons, earning his MD and PhD degrees in 1987.

Rise to Success

After completing his studies, Yancopoulos joined Regeneron Pharmaceuticals in 1989, shortly after its founding. He left academia to become a scientific founder of Regeneron Pharmaceuticals. Working alongside CEO Leonard Schleifer, Yancopoulos has played a pivotal role in transforming Regeneron into a leading biotechnology company. His scientific expertise and leadership have been crucial in the development of the company's innovative technologies and drug candidates. Yancopoulos has been recognized as the first research and development chief in the pharmaceutical industry to become a billionaire.

Key Business Strategies

Yancopoulos spearheaded the development of Regeneron's core technologies, including VelociGene and VelocImmune, which have significantly accelerated drug discovery. He also led the invention of multiple FDA-approved medicines, including Eylea, a treatment for age-related macular degeneration, and Dupixent. Regeneron's business strategy emphasizes in-house innovation and a deep understanding of disease biology, leading to the creation of a diverse portfolio of drugs. Strategic partnerships, such as the collaboration with Sanofi, have also been key to the company's growth.

Philanthropy

Yancopoulos is involved in Regeneron's STEM (Science, Technology, Engineering, and Math) Education commitments, including the Regeneron Science Talent Search.

Career Milestones

1976

Westinghouse Science Talent Search Winner

Yancopoulos was a top winner in the Westinghouse Science Talent Search.

1987

Earned MD and PhD

Received his MD and PhD degrees from Columbia University's College of Physicians & Surgeons.

1989

Joined Regeneron Pharmaceuticals

Became scientific founder.

2004

Elected to National Academy of Sciences and American Academy of Arts and Sciences

Recognized for scientific contributions.

2011

FDA Approval of Eylea

Eylea, a treatment for age-related macular degeneration, received FDA approval.

2016

Ernst & Young Entrepreneur of the Year

Named as Ernst & Young Entrepreneurs of the Year, along with Leonard Schleifer.

Philanthropy & Social Impact

Education

Regeneron Science Talent Search

Undisclosed

Regeneron sponsors the Regeneron Science Talent Search, a prestigious high school science competition.

Business Philosophy & Leadership

Notable Quotes

"I think we do discovery differently and better. And I think part of it is we've really learned how to brainstorm and think inventively in a group."

"Science fails most of the time. But you can't look at it as real failure, but basically an opportunity to learn what could go wrong and then reinvent around it to get back on track."

"We were a relatively small company, but we had the most powerful technology, and sometimes that's what really counts."

Leadership Principles

Embrace Collaboration

Yancopoulos emphasizes the importance of teamwork and synergistic environments in scientific innovation.

Challenge Assumptions

Encourages questioning existing beliefs and assumptions in science to drive discoveries.

Embrace Failure as a Learning Opportunity

Views setbacks as chances to learn and improve, essential for scientific progress.

Focus on Long-Term Vision

Advocates for a long-term commitment to dreams and goals.

Controversies & Challenges

2020

'All Lives Matter' Graduation Speech

Yancopoulos was criticized for a graduation speech.

2021

COVID-19 Tests Access

Accusations of special access to COVID-19 tests.